Robust Two-Photon Visualized Nanocarrier with Dual Targeting Ability for Controlled Chemo-Photodynamic Synergistic Treatment of Cancer

Hao Wan,†‡ Yi Zhang,† Weibing Zhang,*‡ and Hanfa Zou*†

1.Key Lab of Separation Sciences for Analytical Chemistry, National Chromatographic R&A Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, China
2.Shanghai Key Laboratory of Functional Materials Chemistry, East China University of Science and Technology, Shanghai 200237, China

Supporting Information

ABSTRACT: In consideration of the intrinsic complexity of cancer, just being a delivery nanovehicle for the nanocarrier is no longer enough to fulfill requirements of dealing with cancer. In this regard, the multifunctional nanocarrier appears to be an appealing choice in cancer treatment. Herein, the novel multifunctional nanocarrier (Fe3O4 NS-C3N4@mSiO2-PEG-RGD) possessing properties of dual targeting (the peptide- and magnetism-mediated targeting), imaging (one- and two-photon modes), pH-triggered release of loaded anticancer drug, and synergistic treatment (photodynamic therapy (PDT) combined with chemotherapy) are successfully developed. The nanocarrier specifically centralizes within cancer cells with the enhanced amount through the dual targeting ability and is facilely tracked under one- and two-photon imaging modes attributed to the autofluorescence. Then, visible light irradiation-induced PDT combined with low pH-triggered chemotherapy synergistically cooperate to efficiently kill cancer cells. Following the above process, the multifunctional nanocarrier demonstrates effective inhibition of the growth of A549 and HeLa cancer cells. The efficient manipulation of Fe3O4-NS-C3N4@mSiO2-PEG-RGD also implies potential applications of the multifunctional nanocarrier in delivery of different agents. Furthermore, it might also broaden the scope of fabrication of the multifunctional nanocarrier for inhibiting the growth of cancer cells.

KEYWORDS: two-photon imaging, dual targeting, pH-triggered release, chemo-photodynamic synergistic treatment, multifunctional nanocarrier

1. INTRODUCTION

The intricate properties of cancer require a high demand for the nanocarrier, which makes the integration of various functions into one single nanoplatform imperative.1−3 In this regard, the multifunctional nanocarrier possessing targeting, imaging, stimuli response, and synergistic treatment appears to be an appealing alternative to combat cancer, not only for the enhanced uptake by cancer cells accompanied by minimization of the damage to normal cells and facile track of the nanocarrier distribution with simultaneous lighting of the lesion part to optimize the therapeutic scenario, but also for the enhanced therapeutic efficacy compared with the sole therapeutic modality. Dual targeting combining the peptide- and magnetism-mediated targeting exhibits a better way to specifically centralize the nanocarrier within cancer cells with the enhanced amount. Under the magnetic attraction, the nanocarrier would directionally and specifically approach the lesion part, followed by the peptide and magnetism promoting internalization of the nanocarrier, which in turn will enhance the therapeutic efficacy and also attenuate potential side effects toward normal cells to the greatest extent.4−6 Because of its high resolution, precision, sensitivity, and ability to visualize real-time dynamics, fluorescent imaging is a preferred choice in cancer treatment.7,8 However, conventional fluorescent probes with photobleaching, toxicity, and tedious steps of anchoring to the nanocarrier are mostly imaged under one-photon excitation, exhibiting limited tissue penetration, strong interference from intracellular fluorescence of the biological matrix, and potential phototoxicity, seriously affecting the practical application.9−11 In contrast, two-photon imaging activated by the longer wavelength of light demonstrates higher spatial resolution, less photobleaching and photodamage, as well as deeper tissue penetration, more suitable for the biological imaging and sensing.12−16 Therefore, the fluorescent nanomaterial excited by two-photon light appears to be an excellent substrate for the construction of the multifunctional nanocarrier. Meanwhile, as the ideal nanocarrier, the release of loaded drug should be specifically manipulated to make the administration of cancer on-demand, enhancing the therapeutic efficacy as well as attenuating potential side effects to normal cells.17−19 Among all stimuli, pH is meant to be an excellent internal stimulus to trigger the release of drug attributed to the universal lower pH.
(4.5–5.5) within cancer cells compared with normal cells, available for most kinds of cancer issues.\textsuperscript{20–22} Normally, chemotherapy, applying toxic drug against cancer cells, is the conventional way to deal with cancer. In order to attenuate side effects, the amount of applied drug should be strictly controlled to a low extent, and the drug resistant ability of some cancer cells could weaken the potency of the drug, both of which lead to inferior chemotherapy.\textsuperscript{23,24} Photodynamic therapy (PDT), utilizing ROS generated under light irradiation to efficiently kill cancer cells, has sparked increasing attention recently. The noninvasive therapeutic modality enables spatiotemporal treatment with high efficacy but less morbidity and disfigure-
ment.\textsuperscript{25–27} Therefore, synergistic treatment combining both chemotherapy and PDT appears to be a promising way to exploit each other’s merits for the enhancement of the overall therapeutic effect.\textsuperscript{28–30} Given all of the above, the fabrication of the two-photon visualized nanocarrier with the dual targeting ability for controlled chemo-photodynamic synergistic treatment would be attractive in cancer therapy.

As an analogue of graphite, graphitic-phase carbon nitride (g-C\textsubscript{3}N\textsubscript{4}) possesses a stacked 2D structure. Recently, g-C\textsubscript{3}N\textsubscript{4} has been successfully exfoliated by polar water under ultrasonication, and the obtained C\textsubscript{3}N\textsubscript{4} nanosheets (NS-C\textsubscript{3}N\textsubscript{4}) with enhanced fluorescent emission and photocatalytic
performance have been applied in the fluorescent detector, in visible light-induced degradation, and in biological imaging.\textsuperscript{\textcircled{1}-\textcircled{3}} The negligible cytotoxicity plus low photobleaching have enabled NS-C$_3$N$_4$ to be an excellent imaging agent. Moreover, the high cross-section of two photons also made NS-C$_3$N$_4$ visualized under the longer wavelength of light, which is more suitable in cancer treatment because of deeper tissue penetration and less interference from intracellular fluorescence of the biological matrix.\textsuperscript{\textcircled{4}} Meanwhile, the efficient generation of ROS under visible light irradiation also renders NS-C$_3$N$_4$ as a potential PDT agent.\textsuperscript{\textcircled{5}}

It was reported that the decoration of NS-C$_3$N$_4$ with metal or metal oxide nanoparticles would to some extent enhance the efficacy of generation of ROS under visible light irradiation through the increase of separation efficiency of photogenerated electron–hole pairs,\textsuperscript{\textcircled{6}} which herein we assume would benefit the PDT effect.\textsuperscript{\textcircled{2,\textcircled{3,\textcircled{7,\textcircled{8}}}}}

Among these decorations, Fe$_3$O$_4$ nanoparticles seem to be a better choice attributed to an additional arrival of the magnetic response to endow the nanocomposite with a magnetic targeting ability. However, the strongly negative surface is detrimental to the uptake of Fe$_3$O$_4$-NS-C$_3$N$_4$ by cancer cells whose membrane surface is also negative, and the poor modification also limits the manipulation, both of which still hinder the further intracellular application of Fe$_3$O$_4$-NS-C$_3$N$_4$.

Due to easy modification, negligible cytotoxicity, high surface area, and excellent stability, mesoporous silica has been widely employed in the biological field.\textsuperscript{\textcircled{9,\textcircled{10}}} Therefore, the coating of Fe$_3$O$_4$-NS-C$_3$N$_4$ with a mesoporous silica shell (Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$) is meant to enhance the feasibility of being an elaborate drug delivery system. As the novel nanocarrier, Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$ displays certain distinct merits: (1) vertical pore channels of the mesoporous silica shell and the interaction between anticancer drug and NS-C$_3$N$_4$ would together contribute to a high loading capacity; (2) the coating of Fe$_3$O$_4$-NS-C$_3$N$_4$ with the mesoporous silica shell not only enhances the dispersibility and stability of the nanocarrier in the physiological condition but also amplifies the ability for further modification; (3) the autofluorescence of NS-C$_3$N$_4$ would enable the facile track of the nanocarrier distribution with simultaneous imaging of the lesion part; (4) the capacity of generation of ROS under visible light irradiation could realize PDT which would combine with chemotherapy to synergistically treat cancer with the enhanced therapeutic efficacy; (5) the magnetic response would endow the nanocarrier with a magnetic targeting ability.

A targeting molecule (aptamer, antibody, peptide, etc.), showing specifically a high affinity toward certain receptors overexpressed on the membrane surface of cancer cells, has been anchored onto various nanocarriers for the enhanced uptake by cancer cells and minimization of potential side effects to normal cells. Among these molecules, an integrin-binding cell adhesive peptide, arginine-glycine-aspartic acid motif (RGD), has sparked a variety of interests for its universality. RGD is a three-amino-acid sequence with high affinity toward integrin $\alpha_v$$\beta_3$, a tumor angiogenesis biomarker that is up-regulated on tumor endothelial cells and many types of tumor cells.\textsuperscript{\textcircled{41-\textcircled{45}}}

Because of this special property, RGD coupled with Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$ would better fulfill requirements of the multifunctional nanocarrier for cancer treatment.

Herein, for the first time the two-photon visualized nanocarrier with the dual targeting ability for controlled chemo-photodynamic synergistic treatment of cancer was successfully developed. The multifunctional nanocarrier enabled the facile track of the delivery process under one- and two-photon imaging attributed to the autofluorescence and selectively targeted cancer cells contributed from the combination of the peptide- and magnetism-mediated targeting. The dual targeting ability also enhanced the uptake of the nanocarrier by cancer cells, which in turn improved the therapeutic efficacy. The efficient cancer treatment was realized by low pH-triggered chemotherapy coupled with visible light irradiation-induced PDT. With all these advances integrated into one single nanoplatform, the multifunctional nanocarrier is presented to be an excellent drug delivery system in dealing with cancer (Figure 1).

2. EXPERIMENTAL SECTION

2.1. Materials. Hexadecyltrimethylammonium bromide (CTAB), melamine, tetraethyl orthosilicate (TEOS, 99%), and (3-aminopropyl)triethoxysilane (APTEOS, 99%) were purchased from Sigma-Aldrich (St. Louis, MO). RPMI 1640 medium and bovine serum were obtained from Invitrogen (Carlsbad, CA). Ammonium nitrate, ferric chloride, ethylene glycol, sodium hydroxide, isopropanol, and ethanol were obtained from Tianjin Kermel Chemical Reagent (Tianjin). Doxorubicin in the form of hydrochloride salt was purchased from Aladdin Corporation (Shanghai). Maleimide-PEG3500-NHS was purchased from Avanti Polar Lipids Incorporation (Alabaster, AL). c(RGDfC) was purchased from GL Biochem Ltd. (Shanghai). Deionized water used for all experiments was purified with a Milli-Q water system.

2.2. Preparation of Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$-PEG-RGD. Bulk C$_3$N$_4$ was obtained by heating 20 g of melamine at 600 °C for 2 h in air with the ramp of rate 3 °C/min for both heating and cooling processes. To obtain C$_3$N$_4$ nanosheets (NS-C$_3$N$_4$), 1 g of bulk C$_3$N$_4$ was dispersed in 100 mL of water and sonicated for 6 h at 160 W. The resultant solution was then centrifuged at 5000 rpm for 1 h to remove large and residual unexfoliated C$_3$N$_4$ sheets. The determined amount of FeCl$_3$·6H$_2$O (10, 20, and 30 mg), 20 mg of NS-C$_3$N$_4$, and 30 mL of DEG were homogeneously dispersed under sonication for 1 h. Then, 20 mg of CH$_3$COONa was mixed with the above solution. The whole system was transferred into a Teflon autoclave encapsulated within a stainless steel container and heated at 190 °C for 4 h. After a washing step with water and ethanol with the help of a magnet, the resulting product was designated as Fe$_3$O$_4$-NS-C$_3$N$_4$. The obtained Fe$_3$O$_4$-NS-C$_3$N$_4$ was dispersed homogeneously in a mixture of 3.74 g of CTAB and 180 mL of water. The pH of the whole system was adjusted to 11.8 by NaOH or HCl. After mechanical stirring at 80 °C for 30 min, a mixture of 0.5 mL of TEOS and 2 mL of ethanol was added dropwise. The whole system reacted for another 24 h to assemble a mesoporous silica shell onto Fe$_3$O$_4$-NS-C$_3$N$_4$. After a washing step with water and ethanol with the help of a magnet, the obtained product was designated as Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$. To immobilize the targeting peptide onto Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$, APTEOS (1 mL) was added dropwise into the isopropanol solution of Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$. After the solution was mechanically stirred for 24 h at room temperature, amine-modified Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$ was isolated, followed by two washes with isopropanol. The surfactant (CTAB) occupied in the mesoporous channels was extracted with ammonium nitrate ethanolic solution twice at 65 °C. A 10 mg portion of Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$·NH$_3$ was then treated with the PBS buffer containing 25 mg of NHS-PEG-MAL ($M_m = 3500$). After reaction at room temperature for 2 h, the product (Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$-PEG-MAL) was collected by centrifugation and washed with water twice. Finally, 2.5 mg of c(RGDfC) was reacted with Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$-PEG-MAL in the PBS buffer for another 4 h at room temperature (Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$-PEG-RGD). The final product was washed with water several times and dried at room temperature for further use.

2.3. pH-Triggered Release of DOX from Fe$_3$O$_4$-NS-C$_3$N$_4$@mSiO$_2$-PEG-RGD. For the loading process, each centrifugation tube containing a determined amount of DOX, 0.1 mg of Fe$_3$O$_4$-NS-
Research Article

2.4. Confocal Laser Scanning Microscopy (CLSM) Imaging-Based Evaluation of the Dual Targeting Ability of Fe3O4-NS-C3N4@mSiO2-PEG-RGD. AS49 cancer cells were seeded at the number of 1 × 10^4 per well and incubated for 24 h. Two sets of cells were incubated with Fe3O4-NS-C3N4@mSiO2-PEG and Fe3O4-NS-C3N4@mSiO2-PEG-RGD, respectively, for 3 or 6 h. In parallel, a third set of cells was incubated with Fe3O4-NS-C3N4@mSiO2-PEG-RGD under the magnetic attraction. After the nanocarrier not uptaken by cells was washed out with the PBS buffer, the nanocarrier within cells was excited under 405 nm for one-photon imaging and 780 nm for two-photon imaging.

2.5. Flow Cytometry Assay. AS49, MCF-7, and HK-2 cells were seeded at the number of 1 × 10^5 per well and incubated for 24 h. For each sample, two sets of cells were incubated with Fe3O4-NS-C3N4@mSiO2-PEG and Fe3O4-NS-C3N4@mSiO2-PEG-RGD, respectively, at a determined time. In parallel, a third set of cells was incubated with Fe3O4-NS-C3N4@mSiO2-PEG-RGD under the magnetic attraction. After wash out of the nanocarrier not uptaken by cells with the PBS buffer, cells were collected from the well with the help of tryptic digestion. Finally, the intracellular fluorescence was detected by flow cytometry.

2.6. Detection of Intracellular ROS Level. AS49 cancer cells were seeded at the number of 3 × 10^4 per well and incubated for 15 h. Then, Fe3O4-NS-C3N4@mSiO2-PEG at the concentration of 60 μg/mL was added, followed by another 6 h of incubation. After Fe3O4-NS-C3N4@mSiO2-PEG not uptaken by cells was removed by three PBS buffer washes, cells were subsequently immersed in 10 μM DCFH-DA solution for 30 min. After being with the PBS buffer to remove the residual DCFH-DA, cells divided into two groups were irradiated with visible light (450 nm) at the laser power of 40 mW/cm^2 or not for 10 min. The ROS level was then investigated by confocal laser scanning microscopy (CLSM) imaging.

For site-targeted PDT, after sufficient incubation with Fe3O4-NS-C3N4@mSiO2-PEG-RGD and subsequent DCFH-DA, AS49 cancer cells were irradiated at the specific region, and the other region was not. The ROS level of different regions was then investigated by confocal laser scanning microscopy (CLSM) imaging.

2.7. In Vitro Cytotoxicity Assay. AS49 and HeLa cancer cells at the concentration of 5000 per well were seeded in a 96-well plate with 100 μL media. After cells were incubated in a humidified atmosphere of 5% CO2 at 37 °C for 12 h, a series of Fe3O4-NS-C3N4@mSiO2-PEG-RGD species at different concentrations were added. After incubation for another 48 h, the cell viability was measured. For dual targeting chemo-photodynamic synergistic treatment, before adding anything, AS49 and HeLa cancer cells at concentration of 5000 per well were incubated for 24 h. The bare Fe3O4-NS-C3N4@mSiO2-PEG-RGD, DOX-loaded Fe3O4-NS-C3N4@mSiO2-PEG, or DOX-loaded Fe3O4-NS-C3N4@mSiO2-PEG-RGD was added at a concentration equivalent to free DOX. After incubation for 6 h, each well was washed twice by the PBS buffer to remove the nanocarrier or drug not uptaken by cells. Every line of wells was irradiated by visible light for 10 min at the wavelength of 450 nm in the vis-irradiated group (Fe3O4-NS-C3N4@mSiO2-PEG-RGD/DOX), Fe3O4-NS-C3N4@mSiO2-PEG/DOX, Fe3O4-NS-C3N4@mSiO2-PEG-RGD/DOX/vis, and Fe3O4-NS-C3N4@mSiO2-PEG-RGD/DOX/vis/Mag), and the other irradiation conditions were the same as those in the non-visirradiated group (free DOX, Fe3O4-NS-C3N4@mSiO2-PEG-RGD/DOX and Fe3O4-NS-C3N4@mSiO2-PEG/DOX). After incubation for another 8 h, the cell viability was measured.

2.8. Survival States of AS49 Cancer Cells under Optical Microscope Imaging. For the visual identification of survival states of AS49 cancer cells after different treatment, experimental groups were stained with 0.4% Trypan blue for 5 min after different incubation conditions (Fe3O4-NS-C3N4@mSiO2-PEG-RGD/vis, Fe3O4-NS-C3N4@mSiO2-PEG-RGD/DOX/vis, Fe3O4-NS-C3N4@mSiO2-PEG-RGD/DOX/vis/Mag, Fe3O4-NS-C3N4@mSiO2-PEG-RGD/DOX, and Fe3O4-NS-C3N4@mSiO2-PEG/DOX), followed by two washes with the PBS buffer. Images of cells were then taken under an optical microscope.

2.9. Characterizations. Transmission 30 electron microscopy (TEM) was conducted on a JEOL 2000 EX electronic microscope with an accelerating voltage of 120 keV. Fourier transformed infrared (FTIR) spectroscopy characterization was performed on a Thermo Nicolet 380 spectrometer using KBr pellets (Nicolet, WI). The nitrogen adsorption measurement was conducted at −196 °C (liquid nitrogen temperature) using a static-volumetric method on ASAP 2010 (Micromeritics). Pore diameter and distribution curves were calculated by the BJH (Barrett–Joyner–Halenda) method from adsorption branch. UV–vis spectra were recorded on a UV-3101PC Shimadzu spectroscope. The confocal laser scanning microscopy (CLSM) imaging was performed by a FluoViewTM FV1000 confocal laser scanning microscope (Olympus) with an 100× objective. Cells were preplanted in the glass-bottom dishes (NEST). Optical images were taken under an Olympus CXX 41 microscope (Olympus). Powder X-ray diffraction patterns of the samples were collected on a Bruker D8FOCUS X-ray diffractometer. The saturation magnetization curve was obtained at room temperature on a Physical Property Measurement System 9T (Quantum Design, San Diego). EDS element analysis was conducted on the Inca X-Max80 EDS system (Oxford).

3. RESULTS AND DISCUSSION

The process for the fabrication of the multifunctional nanocarrier was illustrated in Figure 1. First, C3N4 nanosheets (NS-C3N4) were synthesized through heat polymerization of melamine coupled with repeated ultrasonication and centrifugation based on a previous study. Then, a solvothermal reaction was conducted to decorate Fe3O4 nanoparticles onto NS-C3N4 (Fe3O4-NS-C3N4). Under the direction of surfactant CTAB, the mesoporous silica shell was subsequently assembled onto Fe3O4-NS-C3N4 (Fe3O4-NS-C3N4@mSiO2). Finally, a PEG linker was utilized to connect Fe3O4-NS-C3N4@mSiO2 with the RGD targeting peptide (Fe3O4-NS-C3N4@mSiO2-PEG-RGD). On the basis of TEM results, after repeated ultrasonication and centrifugation to remove unexfoliated bulk C3N4, the size of NS-C3N4 was decreased to 100–200 nm (Figure 2a and Supporting Information Figure S1), suitable for the intracellular application. Also, the nearly translucent feature of NS-C3N4 solution also demonstrated the material’s ultrathin thickness, further identifying the successful exfoliation of bulk C3N4 (Supporting Information Figure S2). According to previous studies, the effective exfoliation of bulk C3N4 would enhance the fluorescent and photocatalytic ability of C3N4 to enable NS-C3N4 as a potential imaging as well as photodynamic agent. Moreover, it was also reported the decoration of NS-C3N4 with metal or metal oxide nanoparticles could enhance its ability to generate ROS under visible light irradiation through the increase of separation efficiency of photogenerated electron–hole pairs, which we assumed would benefit the PDT effect. Given this, among these nanoparticles here we chose Fe3O4 nanoparticles as the accessory to decorate NS-C3N4, not only for the enhanced generation of ROS under visible light irradiation, but also for an additional arrival of the magnetic response to endow the nanocarrier with a magnetic targeting ability. Numerous Fe3O4 nanoparticles were dotted...
onto NS-C3N4 after the construction of a solvothermal reaction (Figure 2b). The zeta potential of as-synthesized NS-C3N4 was $-31.5$ mV at neutral condition (water solution) and became even more negative when the surrounding environment became more alkali. In view of the alkali condition for the assembly of the mesoporous silica shell, we assumed the electrostatic attraction between negative NS-C3N4 and positive structure director CTAB would facilitate the coating of a well-defined mesoporous silica shell onto Fe3O4-NS-C3N4. As expected, seen from Figure 2c,d, a clear mesoporous silica shell appeared once the sol–gel assembly was completed. As for XRD analysis, compared with bulk, C3N4, Fe3O4-NS-C3N4@mSiO2 showed a much weaker peak resulting from the effective exfoliation at 27.4°, a broad peak between 20° and 30° corresponding to the amorphous silica shell, and diffraction peaks of Fe3O4, all of which further confirmed the successful fabrication of Fe3O4-NS-C3N4@mSiO2 (Figure 3a). And EDS element analysis also illustrated the existing fundamental elements (Fe, Si, C, N, Figure 3b). In order to achieve the peptide-mediated targeting ability, a PEG linker, which could enhance the stability and dispersibility of the nanocarrier in the physiological condition, was then utilized to connect the RGD targeting peptide (specifically recognizing cancer cells overexpressing the integrin $\alpha_v\beta_3$) with Fe3O4-NS-C3N4@mSiO2. Supported by FTIR analysis (Figure 3c), Fe3O4-NS-C3N4@mSiO2 only showed characteristic peaks of the mesoporous silica shell ($1084, 953, \text{ and } 459 \text{ cm}^{-1}$ correspond to $\nu_{\text{as}}\text{Si}--\text{O}--\text{Si}, \nu_{\text{s}}\text{Si}--\text{O}--\text{Si}, \text{ and } \rho\text{Si}--\text{O}--\text{Si}$, respectively), NS-C3N4 (fingerprint peaks within 1000–1900 cm$^{-1}$), and Fe3O4 (Fe–O, 580 cm$^{-1}$). While new peaks corresponding to C–H (2925, 2983 cm$^{-1}$) emerged for Fe3O4-NS-C3N4@mSiO2-PEG-RGD the zeta potential measurement was auxiliary proof for the successful anchor of the RGD targeting peptide (Supporting Information Figure S3). To further directly confirm that the RGD targeting peptide was

![Figure 2. TEM images of (a) NS-C3N4, (b) Fe3O4-NS-C3N4, (c, d) Fe3O4-NS-C3N4@mSiO2-PEG-RGD.](image1)

![Figure 3. (a) XRD analysis of Fe3O4-NS-C3N4@mSiO2 and bulk C3N4. #, *, and & indicate diffraction peaks of C3N4, amorphous silica, and magnetite phase of Fe3O4, respectively. (b) EDS element analysis of Fe3O4-NS-C3N4@mSiO2. (c) FTIR analysis of (c1) NS-C3N4, (c2) Fe3O4-NS-C3N4@mSiO2, and (c3) Fe3O4-NS-C3N4@mSiO2-PEG-RGD. (d) BET and BJH analyses of Fe3O4-NS-C3N4@mSiO2.](image2)
Indeed anchored onto the mesoporous silica shell, we carried out a BCA assay. From Supporting Information Figure S4, it was clearly observed at a determined time only Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4} or Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-NH\textsubscript{2} would not change the color of BCA solution. However, the color turned into purple and even became darker when the amount of the anchored RGD targeting peptide increased. Finally, a N\textsubscript{2} adsorption experiment was used to probe the detailed structure information on Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}. The nitrogen adsorption–desorption isotherm of Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2} showed a typical IV isotherm pattern of the mesoporous material and a characteristic adsorption step in the 0.1–0.3 relative pressure range, which hinted that the nanocarrier possessed a narrow distribution of pore size (Figure 3d). According to results of BET and BJH analyses, the nanocarrier exhibited high surface area of \(16.726 \text{ m}^2/\text{g}\) and large pore volume of \(0.569 \text{ cc/g}\) with the main pore diameter distributed around \(3.058 \text{ nm}\), implying a potentially high loading capacity for the anticancer drug. It is worth mentioning that the as-prepared nanoparticles are quite stable which could be stored in the aqueous environment for at least 5 days or a much longer time in the dry state.

Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD was supposed to be the pH-responsive nanocarrier, and its “on-demand” release pattern was then evaluated. The loading capacity of this nanocarrier toward DOX (a model drug for cancer treatment) could reach as high as \(0.552 \pm 0.20 \text{ g/g}\), which may result from synergistic loading of DOX by NS-C\textsubscript{3}N\textsubscript{4} and pore channels of mSiO\textsubscript{2}. Then, the release behavior of DOX from Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD was carefully investigated at various pH values (4.5, 5.5, and 7.4). Shown as Figure 4, at lower pH (4.5 or 5.5), mimicking the microenvironment of cancer cells, both the release speed and release amount of DOX were higher than those in the case of pH = 7.4 (mimicking the microenvironment of normal cells). To probe the underlying mechanism, a zeta potential experiment was conducted. In detail, when the pH was 7.4, the zeta potential of NS-C\textsubscript{3}N\textsubscript{4} was \(-10.7 \text{ mV}\). If the pH decreased to 5.5 or 4.5, the zeta potential of NS-C\textsubscript{3}N\textsubscript{4} would increase to \(-2.8 \text{ or } 3.27 \text{ mV}\), respectively (all zeta potential measurements were conducted in the PBS buffer).

Many researchers have already indicated the low pH would protonate the DOX which would enhance its solubility in the aqueous environment, leading to an enhanced release from the nanocarrier.\textsuperscript{46,47} In the meantime, we speculated that, in consideration of the permanent positive zeta potential of DOX (\(pK_a = 8.2\)) at the experimental conditions, strongly electronegative NS-C\textsubscript{3}N\textsubscript{4} and mSiO\textsubscript{2} would attract electro-positive DOX when the surrounding pH was 7.4, preventing a burst release. If the surrounding pH decreased to 5.5 or 4.5, the weak electrostatic attraction or the electropulsive force among mSiO\textsubscript{2}, NS-C\textsubscript{3}N\textsubscript{4}, and DOX combined with the enhanced water solubility of DOX attributed to the protonation effect would accelerate the release of DOX, realizing the pH-triggered release pattern for the “on-demand” administration.

Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD with the autofluorescence was meant to be facilely tracked within cells. However, the decoration of NS-C\textsubscript{3}N\textsubscript{4} with Fe\textsubscript{3}O\textsubscript{4} nanoparticles would quench the fluorescent ability of NS-C\textsubscript{3}N\textsubscript{4} to some extent. Shown as Supporting Information Figure S5, the more Fe\textsubscript{3}O\textsubscript{4} nanoparticles were dotted, the more fluorescence was quenched. In order to make Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD still suitable for intracellular imaging, the amount of Fe\textsubscript{3}O\textsubscript{4} nanoparticles should be strictly controlled. After a series of optimizations, the obtained Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD was sufficiently bright to image cells but also with a moderate magnetic response (a saturation magnetization value of \(4 \text{ emu/g}\), Supporting Information Figure S6) for a preconceived magnetic targeting ability. Attributed to ultrahigh photostability shown in Supporting Information Figure S7, the resultant Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD was superbly suitable for a long-term live-cell track, which remained stable and strongly fluorescent in at least 3 h UV irradiation in sharp contrast to conventional dyes, FITC, Lysotracker, and DOX whose fluorescent signals rapidly diminished in <2 h under the same condition.\textsuperscript{48} To intuitively identify the dual targeting (the peptide- and magnetism-mediated targeting) ability of Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD, two sets of A549 cells were incubated with Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG and Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD, respectively, for 3 or 6 h. In parallel, a third set of A549 cells was incubated with Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD under the magnetic attraction. On the basis of CLSM results (Figure 5, blue channel), the uptakes of Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD by A549 cancer cells were both positively related to the incubation time, of which more nanocarriers could be taken in at a longer incubation time. Meanwhile, at the same incubation time, the intracellular fluorescent density was stronger in the case of Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD than that in the case of Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG. In detail, the RGD targeting peptide could specifically recognize the integrin \(\alpha_v\beta_3\) receptor overexpressed on the membrane surface of A549 cancer cells, promoting the internalization of the nanocarrier, which identified the peptide-mediated targeting ability. When a magnet was applied, Fe\textsubscript{3}O\textsubscript{4}-NS-C\textsubscript{3}N\textsubscript{4}@mSiO\textsubscript{2}-PEG-RGD was attracted toward cells to enhance the interaction for the facilitation of internalization, reflected by the stronger intracellular fluorescence compared with the case without the magnetic attraction to confirm the magnetic targeting ability. It was recently reported that NS-C\textsubscript{3}N\textsubscript{4} demonstrated a good two-photon adsorption (TPA) ability, which could simultaneously absorb two near-infrared photons and emit bright fluorescence in the visible light region. And the TPA cross section of NS-C\textsubscript{3}N\textsubscript{4} has a maximum \(\delta\) up to 28 000 GM at 750 nm, orders of magnitude larger than that of previously reported organic dyes.\textsuperscript{49} Inspired by this, another CLSM experiment (Figure 5, green channel) similar to one-
photon imaging was conducted. Instead, this time was based on the two-photon excitation (780 nm). As expected, results were identical to one-photon imaging, demonstrating the robustness and feasibility of this nanocarrier for a two-photon imaging application, which was more suitable for in vivo imaging in the future.

To further quantitatively demonstrate the dual targeting ability, flow cytometry was utilized to dissect the uptake of the nanocarrier by cells. Herein, A549 cancer cells (positively expressing αvβ3 receptor),42 MCF-7 cancer cells (negatively expressing αvβ3 receptor),39 and HK-2 normal cells (negatively expressing αvβ3 receptor)39 were applied in parallel to incubate with different kinds of nanocarriers under various conditions. In the case of A549 cancer cells (Figure 6a), the uptake of Fe3O4-NS-C3N4@mSiO2-PEG-RGD exceeded that of Fe3O4-NS-C3N4@mSiO2-PEG by a great deal with respect to the comparable uptake of these two nanocarriers in both cases of MCF-7 cancer cells and HK-2 normal cells (Figure 6b,c), hinting at the existing peptide-mediated targeting. In the meantime, an increased uptake of Fe3O4-NS-C3N4@mSiO2-PEG-RGD by all A549, MCF-7, and HK-2 cells was obviously observed when a magnet was applied during the incubation, identifying the magnetic targeting ability. On the whole, the flow cytometry experiment combined with the aforementioned CLSM assay provided strong evidence for the dual targeting ability of Fe3O4-NS-C3N4@mSiO2-PEG-RGD.

Graphite carbon nitride (g-C3N4) with a bandgap of 2.7 eV has been reported as an excellent photocatalytic agent (using ROS generated under light irradiation to degrade substances) by many researchers. Also, the effective exfoliation and Fe3O4 nanoparticle decoration of g-C3N4 would enhance its ability to generate ROS under visible light irradiation,10,31,32,44,45 which we assumed would make Fe3O4-NS-C3N4@mSiO2-PEG-RGD as a potential photodynamic agent, enabling PDT. To identify this assumption, the intracellular ROS level of cells treated with Fe3O4-NS-C3N4@mSiO2-PEG-RGD under visible light irradiation was evaluated by CLSM. After sufficient incubation with Fe3O4-NS-C3N4@mSiO2-PEG-RGD and 2,7-dichlorofluorescein (DCFH) (a ROS probe which did not emit fluorescence but emitted strong green fluorescence once oxidized by ROS), A549 cancer cells were irradiated by visible light at the wavelength of 450 nm (40 mW/cm$^2$) or not. Shown as Figure 7, cells in the group with irradiation emitted strong green fluorescence with respect to weak green fluorescence in the group without irradiation, reflecting the efficient ROS generation ability of Fe3O4-NS-C3N4@mSiO2-PEG-RGD under visible light irradiation. Moreover, the confined beam of visible light could also provide site-targeted treatment, which might reduce severe damage toward normal cells during administration. Following this consumption, visible light was constrained to irradiate only one part of the well. Obviously, a boundary emerged in CLSM images (Figure 7e), of which cells in the part with visible light irradiation emitted strong green fluorescence while surrounding cells showed negligible fluorescence, demonstrating the different intracellular ROS

Figure 5. CLSM images of A549 cancer cells after incubation with (a, b) Fe3O4-NS-C3N4@mSiO2-PEG, (c, d) Fe3O4-NS-C3N4@mSiO2-PEG-RGD, and (e, f) Fe3O4-NS-C3N4@mSiO2-PEG-RGD under the magnetic attraction for 3 (a, c, e) or 6 (b, d, f) h. Blue channel was conducted under 405 nm excitation, and green channel was conducted under 780 nm excitation.

Figure 6. Flow cytometry analysis of (a) A549 cancer cells, (b) MCF-7 cancer cells, and (c) HK-2 normal cells incubated with different kinds of nanocarriers under various conditions. Red, blue, green, and black diagrams correspond to groups of control, Fe3O4-NS-C3N4@mSiO2-PEG, Fe3O4-NS-C3N4@mSiO2-PEG-RGD, and Fe3O4-NS-C3N4@mSiO2-PEG-RGD under the magnetic attraction, respectively.
level between these two parts of cells to confirm site-targeted treatment.

Given all aforementioned demonstrations, Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD was supposed to be the excellent nanocarrier with dual targeting chemo-photodynamic synergistic treatment, and the in vitro assay was then systematically investigated. At first, the cytotoxicity of bare Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD toward A549 and HeLa cancer cells (all overexpressing αvβ₃ receptor) was evaluated. Shown in Figure 8, even if the concentration of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD remained as high as 250 μg/mL, the cell viability was still up to 91.94% for A549 cancer cells and 90.78% for HeLa cancer cells after 48 h incubation, validating the negligible cytotoxicity of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD. On account of the ability of generation of ROS under visible light irradiation, Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD would realize intracellular PDT. First, the negligible phototoxicity of visible light at the experimental condition was proven (vis alone, Figure 9a,b, dark blue bar). Inspired by this, a PDT experiment was subsequently conducted (Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/vis). After incubation with Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD at a determined time, cells were irradiated at the wavelength of 450 nm for 10 min. It was obviously found that all experimental groups showed some extent cell death, and the PDT efficacy exhibited a dose-dependent manner (Figure 9a,b, light blue bar). What was worth mentioning was the cell viability decreased to as low as 62.17% and 71.10% for A549 and HeLa cancer cells, respectively, when the applied concentration of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD reached 60 μg/mL, demonstrating efficient PDT. Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD could load DOX and selectively delivered it to cancer cells for the administration of chemotherapy (Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX). After overnight loading of DOX, Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD and Fe₃O₄-NS-C₃N₄@mSiO₂-PEG (Fe₃O₄-NS-C₃N₄@mSiO₂-PEG/DOX) were applied in parallel to incubate with A549 and HeLa cancer cells. To figure out the subcellular localization of the nanocomposite after internalization, Lysotracker probe was used to stain the acidic organelles. Shown as Supporting Information Figure S8, the nanocarrier was mostly trapped within lysosome or endosome, reflected by the yellow merged spots which were a result of overlap between green (Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD) and red (Lysotracker) spots. We speculated the low pH environment in lysosome or endosome would trigger the release of DOX, and the released DOX subsequently diffused into the nucleus to inhibit the synthesis of nucleic acid which finally led to cell apoptosis. Consistent with the consumption, either Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX or Fe₃O₄-NS-C₃N₄@mSiO₂-PEG/DOX exhibited efficient chemotherapy and also showed a dose-dependent manner. Specifically, compared with Fe₃O₄-NS-C₃N₄@mSiO₂-PEG/DOX, Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX expressed the more efficient chemotherapy at every amount attributed to the enhancement of internalization of the nanocarrier by cells mediated by the RGD targeting peptide as described above (Figure 9a,b, black and red bars). In view of the above efficient chemotherapy and PDT, we assumed the combination of these two modalities of treatment might generate a synergistic effect to eventually improve the therapeutic efficacy (Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX/vis). After internalization of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD with loaded DOX, chemotherapy would be activated just as described above, and at the same time cells were irradiated by visible light to activate PDT. Compared with sole chemotherapy or PDT, at every amount synergistic treatment demonstrated the better therapeutic efficacy, implying the high potency to combat cancer (Figure 9a,b, pink bar). And when a magnetic force was applied during the incubation, synergistic treatment exhibited even better therapeutic efficacy, which could be explained by the greater uptake of the nanocarrier by cells that contributed from the

![Figure 7. Intracellular ROS detection of A549 cancer cells incubated with Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD either (c) under visible light irradiation or (a) not; (e) site-targeted PDT. Parts b, d, and f correspond to the optical images of a, c, and e.](image)

![Figure 8. Cytotoxicity of bare Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD toward (a) A549 and (b) HeLa cancer cells after incubation for 48 h.](image)
dual targeting ability as mentioned above (Figure 9a,b, brown bar). To further identify efficient dual targeting synergistic treatment (Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX/vis/Mag), free DOX at the equivalent amount of loaded DOX within Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD was incubated with A549 and HeLa cancer cells, respectively. Because of the direct administration toward cells, free DOX induced more cell death than either treatment alone (Figure 9a,b, green bar). However, as for dual targeting synergistic treatment, the therapeutic efficacy overmatched that of free DOX at every amount in the case of A549 cancer cells and approached toward that of free DOX with the eventual overmatch in the case of HeLa cancer cells. As another piece of evidence, the feasibility of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD for dual targeting synergistic treatment was also evaluated via the observation of survival states of A549 cancer cells treated under different conditions by optical microscopy, in which dead cells were selectively stained with Trypan blue (Figure 10). Intuitively, cells were partially killed under Fe₃O₄-NS-C₃N₄@mSiO₂-PEG/DOX, followed by the modest killing efficacy of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX and Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/vis, respectively. Remarkably, cells were almost killed under the treatment of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX/vis, and better therapeutic efficacy was obtained when a magnet was applied during treatment (Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX/vis/Mag), all of which matched well with the aforementioned cell viability assay, reflecting efficient dual targeting synergistic treatment.

4. CONCLUSIONS

In summary, we elaborately fabricated the novel multifunctional nanocarrier (Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD) by encapsulation of Fe₃O₄ nanoparticle-decorated NS-C₃N₄ within the mesoporous silica shell (mSiO₂) and the subsequent anchor of the RGD targeting peptide onto the outlet of mSiO₂, which was carefully characterized. As for the Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD multifunctional nanocarrier, the following details are relevant: First, NS-C₃N₄ with the autofluorescence enabled one- and two-photon imaging as well as combined with Fe₃O₄ nanoparticles to efficiently generate reactive oxygen species (ROS) under visible light irradiation for the demonstration of PDT. Second, mSiO₂ cooperated with NS-C₃N₄ to load anticancer drug for the realization of low pH-triggered chemotherapy and also enhanced the ability for further modification of the nanocarrier. Finally, the combination of Fe₃O₄ nanoparticles with the RGD targeting peptide endowed the nanocarrier with dual targeting ability to specifically centralize itself within cancer cells with the enhanced amount. Given all advances incorporated into the nanocarrier, Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD demonstrated the enhanced uptake by cancer cells and was facilely tracked within A549 cancer cells under one- and two-photon imaging. The efficient dual targeting chemo-photodynamic synergistic treatment of A549 and HeLa cancer cells by this novel multifunctional nanocarrier could lower the cell viability to 16.37% and 18.85%, respectively, which reflected the potency of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD in cancer treatment.

ASSOCIATED CONTENT

* Supporting Information

DLS analysis of NS-C₃N₄, photo of NS-C₃N₄ solution, zeta potential measurement, photos of BCA solution treated with Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD, photos of Fe₃O₄-NS-C₃N₄@mSiO₂-PEG/DOX, and Fe₃O₄-NS-C₃N₄@mSiO₂-PEG-RGD/DOX/vis/Mag.
C3N4@mSiO2-PEG-RGD with different embedded Fe3O4 nanoparticles under irradiation of a UV hand lamp, room-temperature magnetization curve of Fe3O4-NS-C3N4@mSiO2-PEG-RGD, photos of Fe3O4-NS-C3N4@mSiO2-PEG-RGD solution under UV illumination for 1–3 h, and CLSM of subcellular localization of Fe3O4-NS-C3N4@mSiO2-PEG-RGD. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsami.5b01165.

**AUTHOR INFORMATION**

**Corresponding Authors**
*E-mail: weibingzhang@ecust.edu.cn.*
*E-mail: hanfazou@dicp.ac.cn.*

**Author Contributions**
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

**Notes**
The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**
This work was supported by the China State Key Basic Research Program Grant (2013CB911202, 2012CB910101, 2012CB910604), the Creative Research Group Project of NSFC (21321064), the National Natural Science Foundation of China (21235006, 81161120540), National Key Special Program on Infection Diseases (2012ZX10002009-011), and Analytical Method Innovation Program of MOST (2012IM030900).

**REFERENCES**


(41) He, L.; Huang, Y.; Zhu, H.; Pang, G.; Zheng, W.; Wong, Y.-S.; Chen, T. Cancer-Targeted Monodisperse Mesoporous Silica Nano-